IN8BIO, INC. current report, 19 August 2022

IN8bio, Inc. — Form 8-K Summary

Business context and reporting period

IN8bio, Inc. filed a Form 8-K dated August 19, 2022 under Item 7.01 to report the partial exercise and closing of the underwriters’ option related to a previously announced underwritten public offering. The company is a Delaware corporation headquartered in New York and trades on Nasdaq under the symbol INAB.

Financial metrics and capital structure

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, offering price, gross proceeds, net proceeds, or use-of-proceeds information. It reports the issuance of 268,949 shares of common stock pursuant to the partial exercise of the underwriters’ option.

Material changes versus the prior comparable period

No operating or period-over-period financial results are presented. The reported transaction increases the company’s outstanding common shares and provides additional equity financing, but the filing text does not provide a clear value for the associated proceeds or dilution.

Guidance, outlook, risks, contingencies, and unusual items

  • The filing contains no revenue or earnings guidance and no updated outlook.
  • The transaction was conducted under a previously announced underwritten public offering.
  • The Item 7.01 disclosure and Exhibit 99.1 are furnished rather than filed for purposes of Section 18 of the Exchange Act, and are not incorporated by reference except where expressly stated.
  • Terms not included in the supplied filing text may be described in the referenced press release or related offering documents.

Important facts for investors to verify

  • Offering price per share and total gross and net proceeds.
  • Whether the 268,949 shares were issued under the original underwriting option and the resulting total shares outstanding.
  • Underwriting discounts, commissions, and other offering expenses.
  • Planned use of proceeds and expected effect on liquidity and development activities.
  • Any additional dilution from warrants, options, or other securities issued in connection with the offering.